DiaMedica Therapeutics Inc.(DMAC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DMAC DiaMedica Therapeutics Inc.

休市中 08-14 16:00:00 EDT

6.68

-0.07

-1.04%

盘后6.68

+0.000.00%

19:34 EDT

最高6.79	最低6.55	成交量16.52万
今开6.74	昨收6.75	日振幅3.48%
总市值3.60亿	流通市值1.88亿	总股本5,388万
成交额110.37万	换手率0.59%	流通股本2,820万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DMAC","market":"US","secType":"STK","nameCN":"DiaMedica Therapeutics Inc.","latestPrice":6.68,"timestamp":1786737600000,"preClose":6.75,"halted":0,"volume":165178,"hourTrading":{"tag":"盘后","latestPrice":6.68,"preClose":6.68,"latestTime":"19:34 EDT","volume":131,"amount":874.68,"timestamp":1786750450541,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010370370370370412,"floatShares":28197023,"shares":53882506,"eps":-0.715716,"marketStatus":"休市中","change":-0.07,"latestTime":"08-14 16:00:00 EDT","open":6.74,"high":6.785,"low":6.55,"amount":1103727.0602592,"amplitude":0.034815,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.715716,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":6.75,"postHourTrading":{"tag":"盘后","latestPrice":6.68,"preClose":6.68,"latestTime":"19:34 EDT","volume":131,"amount":874.68,"timestamp":1786750450541,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1438190918584137,"impliedVol":1.3712,"impliedVolPercentile":0.753},"requestUrl":"/m/hq/s/DMAC","defaultTab":"news","newsList":[{"id":"1130899867","title":"DiaMedica Therapeutics 将于2026年8月11日披露第二季度财报并发布业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1130899867","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130899867?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:31","pubTimestamp":1785875475,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc.（DMAC）宣布，计划于2026年8月11日公布其第二季度财务业绩，并同步提供公司最新业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128920352","title":"DiaMedica Therapeutics宣布首批患者入组Dm199治疗胎儿生长受限的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1128920352","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128920352?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:31","pubTimestamp":1782217882,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. 已启动其针对胎儿生长受限（FGR）的潜在疗法Dm199的二期临床试验，并为首批患者完成了给药。这项进展标志着该候选药物在临床开发路径上迈出了关键一步，旨在解决这一目前缺乏有效药物治疗的严重妊娠并发症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108848662","title":"DiaMedica Therapeutics宣布其Remedy2急性缺血性卒中2/3期试验达到75%患者入组里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1108848662","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108848662?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:32","pubTimestamp":1779280323,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. (DMAC) 宣布，其针对急性缺血性卒中的关键性Remedy2 2/3期临床试验，已成功达到75%的患者入组目标。这一进展标志着该试验在推进评估其先导候选药物DM199疗效的进程中，迈出了重要一步。该试验旨在验证DM199在改善卒中患者神经功能恢复方面的潜力，其阶段性成果为后续的数据收集与分析奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190034227","title":"DiaMedica Therapeutics将于2026年5月7日公布2026年第一季度财报并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1190034227","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190034227?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:25","pubTimestamp":1777551912,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. 计划于2026年5月7日发布其2026年第一季度财务业绩报告，届时将同步更新公司最新业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112334028","title":"DiaMedica Therapeutics将于2026年3月31日公布2025年第四季度财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112334028","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112334028?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:27","pubTimestamp":1774268848,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. (DMAC) 宣布，公司计划于2026年3月31日发布2025年第四季度的财务业绩报告。此次公告不仅将披露关键的财务数据，还将同步提供公司最新的业务进展更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114731696","title":"DiaMedica Therapeutics获加拿大卫生部批准启动Dm199治疗先兆子痫的二期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1114731696","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114731696?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:35","pubTimestamp":1772714115,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. (DMAC) 已获得加拿大卫生部的许可，将启动其候选药物Dm199用于治疗先兆子痫的二期临床试验。此项批准标志着该药物在开发进程中迈出了关键一步，为后续研究铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504873948","title":"Diamedica Therapeutics Inc.盘中异动 快速拉升5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504873948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504873948?lang=zh_cn&edition=full","pubTime":"2025-01-17 01:09","pubTimestamp":1737047376,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日01时09分，Diamedica Therapeutics Inc.股票出现波动，股价急速拉升5.58%。截至发稿，该股报5.68美元/股，成交量2.2245万股，换手率0.05%，振幅4.74%。Diamedica Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.19%。其相关个股中，Aeon Biopharma, Inc.、Phio Pharmaceuticals Corp.、Kairos Pharma, Ltd.涨幅较大，Aditxt, Inc.、Phio Pharmaceuticals Corp.、Aeon Biopharma, Inc.较为活跃，换手率分别为1857.39%、668.23%、617.48%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Aeon Biopharma, Inc.、Phio Pharmaceuticals Corp.，振幅分别为131.33%、104.84%、79.70%。Diamedica Therapeutics Inc.公司简介：DiaMedica Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117010936abad7265&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117010936abad7265&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DMAC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2485932112","title":"Diamedica Therapeutics Inc.2024财年第三财季实现净利润-6.27百万美元，同比减少40.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485932112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2485932112?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:01","pubTimestamp":1732291301,"startTime":"0","endTime":"0","summary":"11月23日，Diamedica Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-6.27百万美元，同比减少40.27%；其中营业收入为0.00美元，每股基本收益为-0.15美元。从资产负债表来看，Diamedica Therapeutics Inc.总负债4.56百万美元，其中短期债务102000.00美元，资产负债比为11.52，流动比率为11.81。机构评级：截至2024年11月23日，当前有4家机构对Diamedica Therapeutics Inc.目标价做出预测，其中目标均价为7.00美元，其中最低目标价为6.00美元，最高目标价为8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000202a24e490a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000202a24e490a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2468582619","title":"Diamedica Therapeutics Inc.盘中异动 急速下挫5.98%报4.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468582619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2468582619?lang=zh_cn&edition=full","pubTime":"2024-09-18 22:06","pubTimestamp":1726668361,"startTime":"0","endTime":"0","summary":"北京时间2024年09月18日22时06分，Diamedica Therapeutics Inc.股票出现异动，股价快速跳水5.98%。截至发稿，该股报4.09美元/股，成交量1.5506万股，换手率0.04%，振幅3.17%。Diamedica Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Diamedica Therapeutics Inc.公司简介：DiaMedica Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091822060198e37e78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091822060198e37e78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DMAC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2467740497","title":"Diamedica Therapeutics Inc.盘中异动 早盘股价大涨5.71%报4.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467740497","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2467740497?lang=zh_cn&edition=full","pubTime":"2024-09-13 22:44","pubTimestamp":1726238648,"startTime":"0","endTime":"0","summary":"北京时间2024年09月13日22时44分，Diamedica Therapeutics Inc.股票出现异动，股价大幅上涨5.71%。截至发稿，该股报4.54美元/股，成交量3.86万股，换手率0.09%，振幅6.29%。Diamedica Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Immuneering Corporation、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Windtree Therapeutics, Inc.、Immuneering Corporation、Galmed Pharmaceuticals Ltd.较为活跃，换手率分别为782.28%、333.91%、83.09%，振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Immuneering Corporation、Prelude Therapeutics Incorporated，振幅分别为43.56%、42.66%、36.34%。Diamedica Therapeutics Inc.公司简介：DiaMedica Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091322440898e378cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091322440898e378cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.diamedica.com","stockEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.1257},{"period":"3month","weight":0.1023},{"period":"6month","weight":-0.2169},{"period":"1year","weight":0.1115},{"period":"ytd","weight":-0.1608}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Diamedica Therapeutics Inc.最初是根据《公司法》（马尼托巴省）于2000年1月21日通过公司章程成立的。2019年5月31日，从根据CBCA成立的公司继续存在到根据BCBCA成立的不列颠哥伦比亚省。该公司是一家临床阶段的生物制药公司，致力于改善患有严重疾病的人的生活。Diamedica疗法的主要候选药物DM199是第一个在患者中研究的具有药物活性的重组（合成）形式的人体组织激肽释放酶-1（KLK1）蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.044661},{"month":2,"riseRate":0.75,"avgChangeRate":0.065241},{"month":3,"riseRate":0.125,"avgChangeRate":-0.104653},{"month":4,"riseRate":0.5,"avgChangeRate":0.007808},{"month":5,"riseRate":0.5,"avgChangeRate":0.080466},{"month":6,"riseRate":0.625,"avgChangeRate":0.180786},{"month":7,"riseRate":0.25,"avgChangeRate":-0.115049},{"month":8,"riseRate":0.625,"avgChangeRate":0.049252},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.090818},{"month":10,"riseRate":0.571429,"avgChangeRate":0.039154},{"month":11,"riseRate":0.857143,"avgChangeRate":0.137742},{"month":12,"riseRate":0.571429,"avgChangeRate":0.246007}],"exchange":"NASDAQ","name":"DiaMedica Therapeutics Inc.","nameEN":"DiaMedica Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DiaMedica Therapeutics Inc.(DMAC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供DiaMedica Therapeutics Inc.(DMAC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"DiaMedica Therapeutics Inc.,DMAC,DiaMedica Therapeutics Inc.股票,DiaMedica Therapeutics Inc.股票老虎,DiaMedica Therapeutics Inc.股票老虎国际,DiaMedica Therapeutics Inc.行情,DiaMedica Therapeutics Inc.股票行情,DiaMedica Therapeutics Inc.股价,DiaMedica Therapeutics Inc.股市,DiaMedica Therapeutics Inc.股票价格,DiaMedica Therapeutics Inc.股票交易,DiaMedica Therapeutics Inc.股票购买,DiaMedica Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DiaMedica Therapeutics Inc.(DMAC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供DiaMedica Therapeutics Inc.(DMAC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}